ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Buy" from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have received an average rating of "Buy" from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $80.13.

A number of research firms have recently commented on ANIP. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Truist Financial increased their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Finally, Guggenheim reissued a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the transaction, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company's stock, valued at $4,048,711.50. This trade represents a 1.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,681 shares of company stock valued at $408,498 in the last three months. Corporate insiders own 11.10% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ANIP. Millennium Management LLC boosted its stake in ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares during the last quarter. abrdn plc acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $13,155,000. Aberdeen Group plc boosted its stake in shares of ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock worth $28,059,000 after buying an additional 181,134 shares during the last quarter. Woodline Partners LP purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $11,144,000. Finally, Deep Track Capital LP boosted its stake in shares of ANI Pharmaceuticals by 28.6% in the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after buying an additional 144,214 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Up 0.9%

NASDAQ:ANIP traded up $0.53 during trading hours on Monday, hitting $58.32. 364,442 shares of the company were exchanged, compared to its average volume of 303,166. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -106.04 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $77.00. The company has a fifty day simple moving average of $66.23 and a 200 day simple moving average of $60.79.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The company had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's revenue was up 43.4% compared to the same quarter last year. During the same period last year, the company earned $0.82 earnings per share. Sell-side analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.